A Phase 2 interventional study of Bimekizumab in Chronic Plaque Psoriasis, sponsored by UCB Biopharma SRL. Completed at 10 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-07-22.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing bimekizumab in Psoriasis — 4 open to participants now, 5 under way, 3 of them phase 3. bimekizumab · Psoriasis.
Among the 20 studies testing bimekizumab in Psoriasis, this one is the 16th largest by enrollment, is one of 2 that started in 2017, is one of 6 in phase 2, and was the 5th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →4 of the 20 studies testing bimekizumab in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Canada, China and 10 more countries
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–45
University Hospital, Rouen · Sites in France
Ages 18–60
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 161 across the 20 interventional studies. Of the 15 that completed or were terminated, 12 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 8 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
26 studies in Psoriasis by UCB S.A.: 1 open now, 2 under way, 2 of them phase 3. Of 24 finished, 19 (79%) have results posted.
Among the 26 studies in Psoriasis by UCB S.A., this one is the 23rd largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2017, is one of 7 in phase 2, and was the 12th registered.
UCB S.A.’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing bimekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 26 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
This is a study to assess the long-term safety, tolerability, and efficacy of bimekizumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in this cohort will receive dose 1 every four weeks (Q4W) subcutaneously (sc) during the 48-week open-label Treatment Period. There will be an option to increase the dose to dose 2 Q4W at the discretion of the Investigator if the subject's Psoriasis Area and Severity Index (PASI) response is \>=50% to \<75% reduction from the Baseline of PS0016 at Week 12 or later. If the subject's disease is adequately controlled on dose 2 Q4W, they may return to dose 1 Q4W at the discretion of the Investigator.
Drug: Bimekizumab
Bimekizumab will be administered subcutaneously in 2 different doses.
Also known as: UCB4940
Incidence of Treatment Emergent Adverse Event (TEAE) Adjusted by Duration of Participant Exposure to Treatment
TEAEs were events that had a start date on or after the first administration of study treatment in PS0018 until the last received dose of investigational medicinal product (IMP) +140 days \[which covered the 20-week Safety Follow-Up (SFU) Visit\]. The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the adverse event (AE) being considered. If a participant had no events, the total time at risk was used.
Time frame: From Baseline (Week 0) until Safety Follow Up Visit (up to Week 64)
Plasma Concentration of Bimekizumab During the Study
Plasma concentration of Bimekizumab was expressed in micrograms per milliliter (μg/mL). Values Below Limit of Quantification (BLQ) were replaced by value of Lower Limit of Quantification (LLOQ) divided by 2 (=0.075 μg/mL) in calculations of Means and Coefficient of Variations (CVs). Means and CVs were only calculated if at least 2/3 of the concentrations were quantified at the respective timepoint.
Time frame: From Baseline (Week 0) until Safety Follow Up Visit (up to Week 64)
Percentage of Participants With Positive Anti-bimekizumab (BZK) Antibody Levels Prior to Study Treatment
For a given visit / time point, an Anti-BKZ status of positive was concluded for any participant with an anti-drug antibody (ADA) level that was above cut point (ACP) and CP at that visit/ time point. A participant was classified as overall positive if at least one PS0018 measurement is ACP and CP (this included participants who had negative results at PS0016 Baseline). Percentages were based on the number of participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: Baseline of study PS0016 [NCT03025542]
Percentage of Participants With Overall Positive Anti-bimekizumab (BZK) Antibody Levels Following Study Treatment
For a given visit / time point, an Anti-BKZ status of positive was concluded for any participant with an anti-drug antibody (ADA) level that was above cut point (ACP) and CP at that visit/ time point. A participant was classified as overall positive if at least one PS0018 measurement is ACP and CP (this included participants who had negative results at PS0016 Baseline). Percentages were based on the number of participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Percentage of Participants Achieving a 50% or Higher Improvement in Psoriasis Area and Severity Index (PASI) During the Study
The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The degree of involvement is estimated across 4 body areas; head, upper limbs, trunk, and lower limbs and then transferred into a grade. The Investigator assessed the average redness, thickness, and scaliness of lesions in each body area (each on a 5 - point scale); 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. The PASI50 responses were based on at least 50% improvement in the PASI score at the Baseline of PS0016. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Percentage of Participants Achieving a 75% or Higher Improvement in Psoriasis Area and Severity Index (PASI) During the Study
The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The degree of involvement is estimated across 4 body areas; head, upper limbs, trunk, and lower limbs and then transferred into a grade. The Investigator assessed the average redness, thickness, and scaliness of lesions in each body area (each on a 5 - point scale); 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. The PASI75 responses were based on at least 75% improvement in the PASI score at the Baseline of PS0016. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Percentage of Participants Achieving a 90% or Higher Improvement in Psoriasis Area and Severity Index (PASI) During the Study
The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The degree of involvement is estimated across 4 body areas; head, upper limbs, trunk, and lower limbs and then transferred into a grade. The Investigator assessed the average redness, thickness, and scaliness of lesions in each body area (each on a 5 - point scale); 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. The PASI90 responses were based on at least 90% improvement in the PASI score at the Baseline of PS0016. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI) During the Study
The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The degree of involvement is estimated across 4 body areas; head, upper limbs, trunk, and lower limbs and then transferred into a grade. The Investigator assessed the average redness, thickness, and scaliness of lesions in each body area (each on a 5 - point scale); 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. The PASI100 responses were based on 100% improvement in the PASI score at the Baseline of PS0016. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Percentage of Participants With Investigator´s Global Assessment (IGA) Response (Clear or Almost Clear With at Least a 2 Category Improvement From Baseline on a 5-point Scale) During the Study
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0=Clear to 4=Severe. The response was defined as clear \[0\] or almost clear \[1\] with at least 2 category improvement from PS0016 Baseline. Clear was defined as no signs of PSO; post-inflammatory hyperpigmentation may be present. Almost clear was defined as no thickening; normal to pink coloration; no to minimal focal scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Mean Change From PS0016 [NCT03025542] Baseline in PASI Score During the Study
The total PASI score ranges from 0 to 72 with a reduction from PS0016 Baseline indicating improvement. Missing data was imputed using Last observation carried forward (LOCF) at all visits. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Mean Percentage Change From PS0016 [NCT03025542] Baseline in PASI Score During the Study
A negative percentage change from PS0016 baseline indicated improvement in Total PASI score. The total PASI score ranges from 0 to 72 with a reduction from PS0016 Baseline indicating improvement. Missing data was imputed using Last Observation Carried Forward (LOCF) at all visits. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Percentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Clear IGA Score During the Study
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Clear IGA was defined as no signs of PSO; post-inflammatory hyperpigmentation may be present. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Percentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Almost Clear IGA Score During the Study
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Almost clear was defined as no thickening; normal to pink coloration; no to minimal focal scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Percentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Mild IGA Score During the Study
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Mild was defined as just detectable to mild thickening; pink to light red coloration; predominately fine scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Percentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Moderate IGA Score During the Study
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Percentage of Participants Who Shifted From Moderate Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Severe IGA Score During the Study
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Severe was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Percentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Clear IGA Score During the Study
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Clear was defined as no signs of PSO; post-inflammatory hyperpigmentation may be present. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Percentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Almost Clear IGA Score During the Study
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Almost clear was defined as no thickening; normal to pink coloration; no to minimal focal scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Percentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Mild IGA Score During the Study
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Mild was defined as just detectable to mild thickening; pink to light red coloration; predominately fine scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Percentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Moderate IGA Score During the Study
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Moderate was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Percentage of Participants Who Shifted From Severe Investigator´s Global Assessment (IGA) Score at PS0016 [NCT03025542] Baseline to Severe IGA Score During the Study
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Mean Percentage in the Body Surface Area (BSA) Affected by Psoriasis During the Study
The BSA palm method was used for the evaluation of BSA as follows: Body surface area estimation used the palm (study participant's flat hand and thumb together, fingers included) as representing around 1% of the total BSA. Missing data was imputed using Last Observation Carried forward (LOCF) at all visits. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Mean Percentage Change From PS0016 [NCT03025542] Baseline in the Body Surface Area (BSA) Affected by Psoriasis During the Study
The percentage BSA (0 to 100%) affected by PSO was listed by PS0016 randomized treatment, by study participant and visit including the percentage change from PS0016 Baseline. The BSA palm method was used for the evaluation of BSA as follows: Body surface area estimation used the palm (study participant's flat hand and thumb together, fingers included) as representing around 1% of the total BSA. Missing data was imputed using Last observation carried forward (LOCF) at all visits. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: From Baseline of study PS0016 [NCT03025542] until Safety Follow Up Visit (up to Week 64) of study PS0018
Mean Change From PS0016 [NCT03025542] Baseline in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Score During the Study
HADS-A score is the sum of the 7 individual scores in the anxiety domain and ranges from 0 to 21 with higher scores indicating worse state. A score below 8 was considered normal whereas a score of 15 and above was considered severe. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: Week 0, 12, 24, 36, and 48 of study PS0018, Relative to Baseline of study PS0016 [NCT03025542]
Mean Change From PS0016 [NCT03025542] Baseline in Hospital Anxiety and Depression Scale - Depression (HADS-D) Score During the Study
HADS-D score is the sum of the 7 individual scores in the depression domain and ranges from 0 to 21 with higher scores indicating worse state. A score below 8 was considered normal whereas a score of 15 and above was considered severe. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: Week 0, 12, 24, 36, and 48 of study PS0018, Relative to Baseline of study PS0016 [NCT03025542]
Percentage of Participants With Scores Below 8 in HADS-A (Participants With Normal Scores) During the Study
HADS-A score is the sum of the 7 individual scores in the anxiety domain and ranges from 0 to 21 with higher scores indicating worse state. A score below 8 was considered normal. Percentages were based on the number of participants with a non-missing measurement at the visit. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: Baseline of study PS0016 [NCT03025542], Week 0, 12, 24, 36, and 48 of study PS0018
Percentage of Participants With Scores Below 8 in HADS-D (Participants With Normal Scores) During the Study
HADS-D score is the sum of the 7 individual scores in the depression domain and ranges from 0 to 21 with higher scores indicating worse state. A score below 8 was considered normal. Percentages were based on the number of participants with a non-missing measurement at the visit. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
Time frame: Baseline of study PS0016 [NCT03025542], Week 0, 12, 24, 36, and 48 of study PS0018
The study started to enroll patients in July 2017 and concluded in March 2019.
| Milestone | BKZ All Participants |
|---|---|
| Started | 43 |
| Completed | 37 |
| Not completed | 6 |
| Withdrew: Adverse event | 1 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 3 |
TEAEs were events that had a start date on or after the first administration of study treatment in PS0018 until the last received dose of investigational medicinal product (IMP) +140 days \[which covered the 20-week Safety Follow-Up (SFU) Visit\]. The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the adverse event (AE) being considered. If a participant had no events, the total time at risk was used.
| no. of new events per 100 subject-years | BKZ All Participants (SS) |
|---|---|
| Incidence of Treatment Emergent Adverse Event (TEAE) Adjusted by Duration of Participant Exposure to Treatment | 76.00 (53.8 to 104.3) |
Plasma concentration of Bimekizumab was expressed in micrograms per milliliter (μg/mL). Values Below Limit of Quantification (BLQ) were replaced by value of Lower Limit of Quantification (LLOQ) divided by 2 (=0.075 μg/mL) in calculations of Means and Coefficient of Variations (CVs). Means and CVs were only calculated if at least 2/3 of the concentrations were quantified at the respective timepoint.
| μg/mL | BKZ All Participants (PK-PPS) |
|---|---|
| PS0018 Week 0 | NA ± NA |
| Week 4 | 5.309 ± 47.8 |
| Week 8 | 7.304 ± 60.7 |
| Week 12 | 7.994 ± 53.9 |
| Week 16 | 8.700 ± 53.7 |
| Week 28 | 9.285 ± 49.7 |
| Week 40 | 9.238 ± 51.3 |
| Week 48/ Withdrawal | 9.056 ± 52.5 |
| Follow-up | 0.310 ± 164.8 |
For a given visit / time point, an Anti-BKZ status of positive was concluded for any participant with an anti-drug antibody (ADA) level that was above cut point (ACP) and CP at that visit/ time point. A participant was classified as overall positive if at least one PS0018 measurement is ACP and CP (this included participants who had negative results at PS0016 Baseline). Percentages were based on the number of participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (SS) |
|---|---|
| Percentage of Participants With Positive Anti-bimekizumab (BZK) Antibody Levels Prior to Study Treatment | 2.3 |
For a given visit / time point, an Anti-BKZ status of positive was concluded for any participant with an anti-drug antibody (ADA) level that was above cut point (ACP) and CP at that visit/ time point. A participant was classified as overall positive if at least one PS0018 measurement is ACP and CP (this included participants who had negative results at PS0016 Baseline). Percentages were based on the number of participants with a non-missing measurement, from samples that did not contain BKZ concentration levels above the drug tolerance, at the visit. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (SS) |
|---|---|
| Percentage of Participants With Overall Positive Anti-bimekizumab (BZK) Antibody Levels Following Study Treatment | 25.6 |
The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The degree of involvement is estimated across 4 body areas; head, upper limbs, trunk, and lower limbs and then transferred into a grade. The Investigator assessed the average redness, thickness, and scaliness of lesions in each body area (each on a 5 - point scale); 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. The PASI50 responses were based on at least 50% improvement in the PASI score at the Baseline of PS0016. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | 60.5 (45.6 to 73.6) |
| Week 4 | 95.3 (84.5 to 98.7) |
| Week 8 | 95.3 (84.5 to 98.7) |
| Week 12 | 95.3 (84.5 to 98.7) |
| Week 16 | 97.7 (87.9 to 99.6) |
| Week 20 | 95.3 (84.5 to 98.7) |
| Week 24 | 93.0 (81.4 to 97.6) |
| Week 28 | 93.0 (81.4 to 97.6) |
| Week 32 | 90.7 (78.4 to 96.3) |
| Week 36 | 90.7 (78.4 to 96.3) |
| Week 40 | 88.4 (75.5 to 94.9) |
| Week 44 | 90.7 (78.4 to 96.3) |
| Week 48/ Withdrawal | 88.4 (75.5 to 94.9) |
| Follow-Up | 79.1 (64.8 to 88.6) |
The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The degree of involvement is estimated across 4 body areas; head, upper limbs, trunk, and lower limbs and then transferred into a grade. The Investigator assessed the average redness, thickness, and scaliness of lesions in each body area (each on a 5 - point scale); 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. The PASI75 responses were based on at least 75% improvement in the PASI score at the Baseline of PS0016. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | 44.2 (30.4 to 58.9) |
| Week 4 | 88.4 (75.5 to 94.9) |
| Week 8 | 95.3 (84.5 to 98.7) |
| Week 12 | 90.7 (78.4 to 96.3) |
| Week 16 | 93.0 (81.4 to 97.6) |
| Week 20 | 90.7 (78.4 to 96.3) |
| Week 24 | 90.7 (78.4 to 96.3) |
| Week 28 | 88.4 (75.5 to 94.9) |
| Week 32 | 90.7 (78.4 to 96.3) |
| Week 36 | 90.7 (78.4 to 96.3) |
| Week 40 | 86.0 (72.7 to 93.4) |
| Week 44 | 90.7 (78.4 to 96.3) |
| Week 48/ Withdrawal | 86.0 (72.7 to 93.4) |
| Follow-Up | 65.1 (50.2 to 77.6) |
The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The degree of involvement is estimated across 4 body areas; head, upper limbs, trunk, and lower limbs and then transferred into a grade. The Investigator assessed the average redness, thickness, and scaliness of lesions in each body area (each on a 5 - point scale); 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. The PASI90 responses were based on at least 90% improvement in the PASI score at the Baseline of PS0016. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | 20.9 (11.4 to 35.2) |
| Week 4 | 53.5 (38.9 to 67.5) |
| Week 8 | 79.1 (64.8 to 88.6) |
| Week 12 | 79.1 (64.8 to 88.6) |
| Week 16 | 86.0 (72.7 to 93.4) |
| Week 20 | 79.1 (64.8 to 88.6) |
| Week 24 | 79.1 (64.8 to 88.6) |
| Week 28 | 81.4 (67.4 to 90.3) |
| Week 32 | 81.4 (67.4 to 90.3) |
| Week 36 | 86.0 (72.7 to 93.4) |
| Week 40 | 76.7 (62.3 to 86.8) |
| Week 44 | 86.0 (72.7 to 93.4) |
| Week 48/ Withdrawal | 79.1 (64.8 to 88.6) |
| Follow-Up | 58.1 (43.3 to 71.6) |
The PASI quantifies the severity and extent of the disease and weighs these with the percentage of body surface area (BSA) involvement. The degree of involvement is estimated across 4 body areas; head, upper limbs, trunk, and lower limbs and then transferred into a grade. The Investigator assessed the average redness, thickness, and scaliness of lesions in each body area (each on a 5 - point scale); 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. The PASI100 responses were based on 100% improvement in the PASI score at the Baseline of PS0016. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | 4.7 (1.3 to 15.5) |
| Week 4 | 23.3 (13.2 to 37.7) |
| Week 8 | 37.2 (24.4 to 52.1) |
| Week 12 | 46.5 (32.5 to 61.1) |
| Week 16 | 39.5 (26.4 to 54.4) |
| Week 20 | 48.8 (34.6 to 63.2) |
| Week 24 | 41.9 (28.4 to 56.7) |
| Week 28 | 46.5 (32.5 to 61.1) |
| Week 32 | 41.9 (28.4 to 56.7) |
| Week 36 | 41.9 (28.4 to 56.7) |
| Week 40 | 46.5 (32.5 to 61.1) |
| Week 44 | 46.5 (32.5 to 61.1) |
| Week 48/ Withdrawal | 46.5 (32.5 to 61.1) |
| Follow-Up | 18.6 (9.7 to 32.6) |
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0=Clear to 4=Severe. The response was defined as clear \[0\] or almost clear \[1\] with at least 2 category improvement from PS0016 Baseline. Clear was defined as no signs of PSO; post-inflammatory hyperpigmentation may be present. Almost clear was defined as no thickening; normal to pink coloration; no to minimal focal scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | 18.6 (9.7 to 32.6) |
| Week 4 | 62.8 (47.9 to 75.6) |
| Week 8 | 79.1 (64.8 to 88.6) |
| Week 12 | 79.1 (64.8 to 88.6) |
| Week 16 | 81.4 (67.4 to 90.3) |
| Week 20 | 79.1 (64.8 to 88.6) |
| Week 24 | 76.7 (62.3 to 86.8) |
| Week 28 | 79.1 (64.8 to 88.6) |
| Week 32 | 86.0 (72.7 to 93.4) |
| Week 36 | 81.4 (67.4 to 90.3) |
| Week 40 | 79.1 (64.8 to 88.6) |
| Week 44 | 83.7 (70.0 to 91.9) |
| Week 48/ Withdrawal | 79.1 (64.8 to 88.6) |
| Follow-Up | 51.2 (36.8 to 65.4) |
The total PASI score ranges from 0 to 72 with a reduction from PS0016 Baseline indicating improvement. Missing data was imputed using Last observation carried forward (LOCF) at all visits. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| score on a scale | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | -11.21 ± 9.13 |
| Week 4 | -16.79 ± 6.72 |
| Week 8 | -18.12 ± 7.41 |
| Week 12 | -18.70 ± 7.89 |
| Week 16 | -19.01 ± 8.70 |
| Week 20 | -18.91 ± 8.70 |
| Week 24 | -19.08 ± 8.66 |
| Week 28 | -19.13 ± 8.79 |
| Week 32 | -19.30 ± 8.66 |
| Week 36 | -19.27 ± 8.68 |
| Week 40 | -19.22 ± 8.82 |
| Week 44 | -19.32 ± 8.68 |
| Week 48/ Withdrawal | -19.20 ± 8.76 |
| Follow-up | -15.93 ± 9.29 |
A negative percentage change from PS0016 baseline indicated improvement in Total PASI score. The total PASI score ranges from 0 to 72 with a reduction from PS0016 Baseline indicating improvement. Missing data was imputed using Last Observation Carried Forward (LOCF) at all visits. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage change | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | -56.45 ± 38.26 |
| Week 4 | -87.71 ± 15.52 |
| Week 8 | -93.28 ± 12.13 |
| Week 12 | -94.50 ± 8.22 |
| Week 16 | -95.15 ± 8.43 |
| Week 20 | -94.84 ± 9.02 |
| Week 24 | -95.69 ± 6.77 |
| Week 28 | -95.72 ± 7.35 |
| Week 32 | -96.85 ± 4.81 |
| Week 36 | -96.66 ± 4.88 |
| Week 40 | -96.13 ± 6.38 |
| Week 44 | -96.98 ± 4.14 |
| Week 48/ Withdrawal | -96.10 ± 7.45 |
| Follow-Up | -81.98 ± 25.45 |
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Clear IGA was defined as no signs of PSO; post-inflammatory hyperpigmentation may be present. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | 4.7 |
| Week 4 | 23.3 |
| Week 8 | 37.2 |
| Week 12 | 44.2 |
| Week 16 | 34.9 |
| Week 20 | 41.9 |
| Week 24 | 37.2 |
| Week 28 | 39.5 |
| Week 32 | 37.2 |
| Week 36 | 37.2 |
| Week 40 | 37.2 |
| Week 44 | 37.2 |
| Week 48/ Withdrawal | 39.5 |
| Follow-Up | 18.6 |
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Almost clear was defined as no thickening; normal to pink coloration; no to minimal focal scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | 11.6 |
| Week 4 | 37.2 |
| Week 8 | 32.6 |
| Week 12 | 23.3 |
| Week 16 | 37.2 |
| Week 20 | 23.3 |
| Week 24 | 30.2 |
| Week 28 | 30.2 |
| Week 32 | 37.2 |
| Week 36 | 30.2 |
| Week 40 | 27.9 |
| Week 44 | 32.6 |
| Week 48/ Withdrawal | 25.6 |
| Follow-Up | 30.2 |
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Mild was defined as just detectable to mild thickening; pink to light red coloration; predominately fine scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | 25.6 |
| Week 4 | 18.6 |
| Week 8 | 14.0 |
| Week 12 | 11.6 |
| Week 16 | 9.3 |
| Week 20 | 14.0 |
| Week 24 | 9.3 |
| Week 28 | 7.0 |
| Week 32 | 2.3 |
| Week 36 | 9.3 |
| Week 40 | 9.3 |
| Week 44 | 2.3 |
| Week 48/ Withdrawal | 7.0 |
| Follow-Up | 11.6 |
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | 25.6 |
| Week 4 | 4.7 |
| Week 8 | 0 |
| Week 12 | 2.3 |
| Week 16 | 2.3 |
| Week 20 | 2.3 |
| Week 24 | 2.3 |
| Week 28 | 2.3 |
| Week 32 | 0 |
| Week 36 | 0 |
| Week 40 | 2.3 |
| Week 44 | 4.7 |
| Week 48/ Withdrawal | 4.7 |
| Follow-Up | 11.6 |
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Moderate IGA was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Severe was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | 16.3 |
| Week 4 | 0 |
| Week 8 | 0 |
| Week 12 | 0 |
| Week 16 | 0 |
| Week 20 | 0 |
| Week 24 | 0 |
| Week 28 | 0 |
| Week 32 | 0 |
| Week 36 | 0 |
| Week 40 | 0 |
| Week 44 | 0 |
| Week 48/ Withdrawal | 0 |
| Follow-Up | 4.7 |
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Clear was defined as no signs of PSO; post-inflammatory hyperpigmentation may be present. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | 0 |
| Week 4 | 0 |
| Week 8 | 0 |
| Week 12 | 2.3 |
| Week 16 | 4.7 |
| Week 20 | 7.0 |
| Week 24 | 4.7 |
| Week 28 | 7.0 |
| Week 32 | 4.7 |
| Week 36 | 7.0 |
| Week 40 | 11.6 |
| Week 44 | 9.3 |
| Week 48/ Withdrawal | 9.3 |
| Follow-Up | 0 |
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Almost clear was defined as no thickening; normal to pink coloration; no to minimal focal scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | 2.3 |
| Week 4 | 2.3 |
| Week 8 | 9.3 |
| Week 12 | 9.3 |
| Week 16 | 4.7 |
| Week 20 | 7.0 |
| Week 24 | 4.7 |
| Week 28 | 2.3 |
| Week 32 | 7.0 |
| Week 36 | 7.0 |
| Week 40 | 2.3 |
| Week 44 | 4.7 |
| Week 48/ Withdrawal | 4.7 |
| Follow-Up | 2.3 |
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Mild was defined as just detectable to mild thickening; pink to light red coloration; predominately fine scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | 2.3 |
| Week 4 | 9.3 |
| Week 8 | 2.3 |
| Week 12 | 0 |
| Week 16 | 4.7 |
| Week 20 | 0 |
| Week 24 | 4.7 |
| Week 28 | 4.7 |
| Week 32 | 2.3 |
| Week 36 | 0 |
| Week 40 | 0 |
| Week 44 | 0 |
| Week 48/ Withdrawal | 0 |
| Follow-Up | 7.0 |
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Moderate was defined as clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | 2.3 |
| Week 4 | 2.3 |
| Week 8 | 0 |
| Week 12 | 2.3 |
| Week 16 | 0 |
| Week 20 | 0 |
| Week 24 | 0 |
| Week 28 | 0 |
| Week 32 | 0 |
| Week 36 | 0 |
| Week 40 | 0 |
| Week 44 | 0 |
| Week 48/ Withdrawal | 0 |
| Follow-Up | 2.3 |
A static IGA for Psoriasis (PSO) was used to assess disease severity in all study participants during the study. IGA is a 5 point scale ranging from 0 = Clear to 4 = Severe. Severe IGA was defined as severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | 9.3 |
| Week 4 | 2.3 |
| Week 8 | 2.3 |
| Week 12 | 0 |
| Week 16 | 0 |
| Week 20 | 0 |
| Week 24 | 0 |
| Week 28 | 0 |
| Week 32 | 0 |
| Week 36 | 0 |
| Week 40 | 0 |
| Week 44 | 0 |
| Week 48/ Withdrawal | 0 |
| Follow-Up | 2.3 |
The BSA palm method was used for the evaluation of BSA as follows: Body surface area estimation used the palm (study participant's flat hand and thumb together, fingers included) as representing around 1% of the total BSA. Missing data was imputed using Last Observation Carried forward (LOCF) at all visits. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of BSA | BKZ All Participants (FAS) |
|---|---|
| PS0016 Baseline | 25.8 ± 17.5 |
| PS0018 Week 0 | 8.6 ± 10.7 |
| Week 4 | 5.2 ± 12.6 |
| Week 8 | 3.0 ± 10.9 |
| Week 12 | 2.0 ± 4.8 |
| Week 16 | 1.0 ± 1.6 |
| Week 20 | 1.2 ± 2.2 |
| Week 24 | 1.2 ± 1.9 |
| Week 28 | 0.9 ± 1.6 |
| Week 32 | 0.8 ± 1.1 |
| Week 36 | 0.7 ± 1.1 |
| Week 40 | 0.8 ± 1.2 |
| Week 44 | 0.7 ± 1.0 |
| Week 48/ Withdrawal | 0.7 ± 1.2 |
| Follow-Up | 4.8 ± 13.0 |
The percentage BSA (0 to 100%) affected by PSO was listed by PS0016 randomized treatment, by study participant and visit including the percentage change from PS0016 Baseline. The BSA palm method was used for the evaluation of BSA as follows: Body surface area estimation used the palm (study participant's flat hand and thumb together, fingers included) as representing around 1% of the total BSA. Missing data was imputed using Last observation carried forward (LOCF) at all visits. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage change | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | -61.0 ± 41.5 |
| Week 4 | -83.0 ± 23.7 |
| Week 8 | -91.1 ± 15.9 |
| Week 12 | -92.9 ± 10.9 |
| Week 16 | -95.5 ± 7.4 |
| Week 20 | -94.4 ± 9.1 |
| Week 24 | -94.8 ± 7.8 |
| Week 28 | -95.4 ± 8.7 |
| Week 32 | -96.1 ± 6.7 |
| Week 36 | -96.5 ± 5.7 |
| Week 40 | -95.8 ± 8.5 |
| Week 44 | -96.3 ± 6.2 |
| Week 48/ Withdrawal | -95.6 ± 10.0 |
| Follow-Up | -81.5 ± 33.9 |
HADS-A score is the sum of the 7 individual scores in the anxiety domain and ranges from 0 to 21 with higher scores indicating worse state. A score below 8 was considered normal whereas a score of 15 and above was considered severe. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| score on a scale | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | -1.5 ± 2.3 |
| Week 12 | -2.0 ± 1.8 |
| Week 24 | -2.0 ± 2.4 |
| Week 36 | -2.0 ± 2.4 |
| Week 48/ Withdrawal | -1.5 ± 2.2 |
HADS-D score is the sum of the 7 individual scores in the depression domain and ranges from 0 to 21 with higher scores indicating worse state. A score below 8 was considered normal whereas a score of 15 and above was considered severe. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| score on a scale | BKZ All Participants (FAS) |
|---|---|
| PS0018 Week 0 | -1.0 ± 1.4 |
| Week 12 | -0.8 ± 2.1 |
| Week 24 | -1.0 ± 1.7 |
| Week 36 | -1.1 ± 1.7 |
| Week 48/ Withdrawal | -1.0 ± 1.8 |
HADS-A score is the sum of the 7 individual scores in the anxiety domain and ranges from 0 to 21 with higher scores indicating worse state. A score below 8 was considered normal. Percentages were based on the number of participants with a non-missing measurement at the visit. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0016 Baseline | 83.7 |
| PS0018 Week 0 | 88.4 |
| Week 12 | 95.2 |
| Week 24 | 90.5 |
| Week 36 | 89.7 |
| Week 48/ Withdrawal | 87.2 |
HADS-D score is the sum of the 7 individual scores in the depression domain and ranges from 0 to 21 with higher scores indicating worse state. A score below 8 was considered normal. Percentages were based on the number of participants with a non-missing measurement at the visit. Baseline was defined as the last available value prior to the first injection of study medication in the PS0016 study.
| percentage of participants | BKZ All Participants (FAS) |
|---|---|
| PS0016 Baseline | 93.0 |
| PS0018 Week 0 | 97.7 |
| Week 12 | 95.2 |
| Week 24 | 97.6 |
| Week 36 | 94.9 |
| Week 48/ Withdrawal | 97.4 |
Collected over Adverse events were collected from the PS0018 Baseline until the Safety Follow-Up Visit [20 weeks after the last dose (up to Week 64)]. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BKZ All Participants (SS) | 0/43 (0%) | 3/43 (7%) | 27/43 (62.8%) |
| Event | BKZ All Participants (SS) |
|---|---|
| Acute myocardial infarctionCardiac disorders | 1/43 |
| Anaemia postoperativeInjury, poisoning and procedural complications | 1/43 |
| SyncopeNervous system disorders | 1/43 |
| Event | BKZ All Participants (SS) |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 8/43 |
| NasopharyngitisInfections and infestations | 7/43 |
| Viral upper respiratory tract infectionInfections and infestations | 5/43 |
| Gamma-glutamyltransferase increasedInvestigations | 5/43 |
| Oral candidiasisInfections and infestations | 4/43 |
| Alanine aminotransferase increasedInvestigations | 4/43 |
| PharyngitisInfections and infestations | 3/43 |
| Staphylococcal pharyngitisInfections and infestations | 3/43 |
Baseline Characteristics refer to the Safety Set which consisted of all study participants who received at least 1 dose of investigational medicinal product (IMP) in PS0018.
| Age, Categorical(Participants) | BKZ All Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 40 |
| >=65 years | 3 |
| Age, Continuous(years) | BKZ All Participants |
|---|---|
| Mean | 45.0 ± 12.8 |
| Sex: Female, Male(Participants) | BKZ All Participants |
|---|---|
| Female | 20 |
| Male | 23 |
| Race/Ethnicity, Customized(Participants) | BKZ All Participants |
|---|---|
| Asian | 4 |
| Black or African American | 1 |
| Native Hawaiian or Other Pacific Islander | 1 |
| White | 37 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2017 to primary completion in Mar 2019, 20 months.
Results were first posted in Mar 2022, 3 years after primary completion. A results delay was requested in Mar 2020.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 20 months is above that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimekizumab